Physician profile
Beth E Yegerlehner
NPI 1275534356
$1,373.27
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $173 · 2021: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $296.75 | 2019-2020 | |
| Novo Nordisk INC | $223.33 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.34 | 2019 | |
| Abbvie INC. | $139.29 | 2019-2020 | |
| Nevro Corp. | $136.85 | 2019 | |
| Merck Sharp & Dohme LLC | $125.66 | 2019 | |
| Amarin Pharma, INC. | $99.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $35.93 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $25.26 | 2019 | |
| Allergan, INC. | $19.34 | 2019 | |
| Sanofi Pasteur INC. | $14.17 | 2019 | |
| Pfizer INC. | $13.29 | 2019 | |
| Eisai INC. | $12.89 | 2019 | |
| Lilly USA, LLC | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Yegerlehner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.